Jürgen Krauter

Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia

Claudio Lottaz, Stefan Fröhling, Jonathan R Pollack, 2007 .

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Axel Benner, Stefan Fröhling, Lars Bullinger, 2008, The New England journal of medicine.

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

Michael Heuser, Katharina Wagner, Brigitte Schlegelberger, 2010, Blood.

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.

Ulrich Lehmann, Ute Modlich, Michael Heuser, 2013, Blood.

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.

Erdogan Taskesen, Bob Löwenberg, Bas J. Wouters, 2011, Blood.

A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1)

Filippo Castiglione, Fabrizio Stracci, Torsten Haferlach, 2008, Haematologica.

Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.

Michael Heuser, Brigitte Schlegelberger, Arnold Ganser, 2012, Blood.

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis

Michael Heuser, Katharina Wagner, Brigitte Schlegelberger, 2010, Haematologica.

A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations

Michael Heuser, Daniela Weber, Hartmut Döhner, 2015, British journal of haematology.

Measurable Residual Disease Monitoring in Acute Myeloid Leukemia with t(8;21)(q22;q22.1): Results of the AML Study Group.

Verena I Gaidzik, Thomas Schroeder, Thomas Kindler, 2019, Blood.

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.

Michael Stadler, Verena I Gaidzik, Michael Heuser, 2018, Blood.

RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.

Verena I Gaidzik, Lars Bullinger, Brigitte Schlegelberger, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.